John J.V. McMurray
Impact in
- Cardiology and Cardiovascular Medicine top 0.01%
- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Blood Pressure and Hypertension Studies
- Atrial Fibrillation Management and Outcomes
- Endocrinology, Diabetes and Metabolism top 0.01%
- Diabetes Treatment and Management
- Hormonal Regulation and Hypertension
Papers in
-
- Heart Failure Treatment and Management 530
- Cardiovascular Function and Risk Factors 232
- Cardiac pacing and defibrillation studies 78
- Atrial Fibrillation Management and Outcomes 47
- Blood Pressure and Hypertension Studies 46
- Cardiac electrophysiology and arrhythmias 42
-
- Diabetes Treatment and Management 174
- Hormonal Regulation and Hypertension 74
- Co-authors
- Karl Swedberg (208 shared papers)Scott D. Solomon (251 shared papers)Marc A. Pfeffer (230 shared papers)Simon Stewart (47 shared papers)Salim Yusuf (81 shared papers)Michael R. Zile (219 shared papers)Eric L. Michelson (50 shared papers)Christopher B. Granger (91 shared papers)
- Journals
- European Journal of Heart Failure (239 papers)Journal of the American College of Cardiology (144 papers)European Heart Journal (144 papers)Circulation (101 papers)JACC Heart Failure (83 papers)
- Partner nations
- United KingdomUnited StatesCanada
In The Last Decade
John J.V. McMurray
1.5k papers receiving 128.9k citations
John J.V. McMurray's Hit Papers
Peers
Comparison fields: 5 of 204
- Cardiology and Cardiovascular Medicine 69.2k
- Endocrinology, Diabetes and Metabolism 24.9k
- Nephrology 6.1k
- Family Practice 914
- Surgery 16.2k
Countries citing papers authored by John J.V. McMurray
This map shows the geographic impact of John J.V. McMurray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John J.V. McMurray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John J.V. McMurray more than expected).
Fields of papers citing papers by John J.V. McMurray
This network shows the impact of papers produced by John J.V. McMurray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John J.V. McMurray. The network helps show where John J.V. McMurray may publish in the future.
Co-authors
The 25 scholars most cited alongside John J.V. McMurray, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.5k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Hit paper breakdown → | 1994 | 6912 |
| 2 | Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure Hit paper breakdown → | 2014 | 4433 |
| 3 | Dapagliflozin in Patients with Chronic Kidney Disease Hit paper breakdown → | 2020 | 3253 |
| 4 | Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms Hit paper breakdown → | 2010 | 2075 |
| 5 | Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Hit paper breakdown → | 2003 | 2056 |
| 6 | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Hit paper breakdown → | 2003 | 1796 |
| 7 | Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome Hit paper breakdown → | 2015 | 1763 |
| 8 | Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both Hit paper breakdown → | 2003 | 1680 |
| 9 | Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention Hit paper breakdown → | 2005 | 1572 |
| 10 | Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction Hit paper breakdown → | 2004 | 1506 |
| 11 | Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome Hit paper breakdown → | 2012 | 1487 |
| 12 | A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease Hit paper breakdown → | 2009 | 1441 |
| 13 | Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 Hit paper breakdown → | 2020 | 1431 |
| 14 | Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction Hit paper breakdown → | 2008 | 1381 |
| 15 | Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Hit paper breakdown → | 2003 | 1340 |
| 16 | A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study Hit paper breakdown → | 2002 | 1182 |
| 17 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Hit paper breakdown → | 2019 | 1143 |
| 18 | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Hit paper breakdown → | 2003 | 1121 |
| 19 | Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Hit paper breakdown → | 2009 | 1011 |
| 20 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Hit paper breakdown → | 2021 | 993 |
About John J.V. McMurray
John J.V. McMurray is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine, Surgery and Nephrology, having authored 1.5k papers that have together received 133.1k indexed citations. Recurring topics across this work include Heart Failure Treatment and Management (530 papers), Cardiovascular Function and Risk Factors (232 papers), Diabetes Treatment and Management (174 papers), Cardiac pacing and defibrillation studies (78 papers), Hormonal Regulation and Hypertension (74 papers), Atrial Fibrillation Management and Outcomes (47 papers), Blood Pressure and Hypertension Studies (46 papers) and Cardiac electrophysiology and arrhythmias (42 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (69.2k citations), Endocrinology, Diabetes and Metabolism (24.9k citations), Nephrology (6.1k citations), Family Practice (914 citations) and Surgery (16.2k citations). John J.V. McMurray has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Karl Swedberg, Scott D. Solomon, Marc A. Pfeffer, Simon Stewart, Salim Yusuf, Michael R. Zile, Eric L. Michelson, Christopher B. Granger, Milton Packer and Lars Køber. Their work appears in journals such as European Journal of Heart Failure, Journal of the American College of Cardiology, European Heart Journal, Circulation and JACC Heart Failure.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.